Inspired by the use of nanotechnology in cancer treatment [105,106,107], Meir et al. conjugated the anti-PD-L1 antibody αPDL1 with gold nanoparticles (GNPs) to develop a theranostic approach for the PD-1/PD-L1 immune checkpoint axis [72]. This evidence concerns the gene PDCD1 and cancer.